Onco-Innovations CEO Thomas O’Shaughnessy Featured on Conversations That Matter to Discuss Breakthroughs in Cancer Treatment, AI Integration, and Potential Global Expansion
Onco-Innovations (OTCQB:ONNVF) CEO Thomas O'Shaughnessy was featured in an exclusive interview on Conversations That Matter, discussing the company's developments in cancer treatment and AI integration. The interview highlighted:
The company's focus on developing novel treatment for colorectal cancer and solid tumors, utilizing precision medicine to enhance traditional therapies. Their proprietary technology, developed by University of Alberta Cancer Institute scientists, employs targeted inhibitors and nanotechnology to disrupt cancer cell replication while preserving healthy tissue.
The interview also covered their recent acquisition of Inka Health AI, which is developing AI tools to optimize patient identification and enhance clinical trial efficacy. The company maintains strategic partnerships with Quantify Research and AstraZeneca Canada to advance precision medicine approaches in cancer therapeutic development.
Onco-Innovations (OTCQB:ONNVF) Il CEO Thomas O'Shaughnessy è stato protagonista di un'intervista esclusiva su Conversations That Matter, in cui ha discusso degli sviluppi dell'azienda nel trattamento del cancro e nell'integrazione dell'IA. L'intervista ha messo in evidenza:
Il focus dell'azienda nello sviluppo di trattamenti innovativi per il cancro colorettale e i tumori solidi, utilizzando la medicina di precisione per migliorare le terapie tradizionali. La loro tecnologia proprietaria, sviluppata dai scienziati dell'Istituto Oncologico dell'Università di Alberta, impiega inibitori mirati e nanotecnologie per interrompere la replicazione delle cellule tumorali preservando il tessuto sano.
L'intervista ha anche trattato della loro recente acquisizione di Inka Health AI, che sta sviluppando strumenti di IA per ottimizzare l'identificazione dei pazienti e migliorare l'efficacia delle sperimentazioni cliniche. L'azienda mantiene partenariati strategici con Quantify Research e AstraZeneca Canada per avanzare negli approcci di medicina di precisione nello sviluppo terapeutico del cancro.
Onco-Innovations (OTCQB:ONNVF) El CEO Thomas O'Shaughnessy fue destacado en una entrevista exclusiva en Conversations That Matter, donde discutió los desarrollos de la empresa en el tratamiento del cáncer y la integración de la IA. La entrevista resaltó:
El enfoque de la empresa en desarrollar tratamientos novedosos para el cáncer colorrectal y tumores sólidos, utilizando medicina de precisión para mejorar las terapias tradicionales. Su tecnología patentada, desarrollada por científicos del Instituto del Cáncer de la Universidad de Alberta, emplea inhibidores dirigidos y nanotecnología para interrumpir la replicación de células cancerosas mientras preserva el tejido sano.
La entrevista también cubrió su reciente adquisición de Inka Health AI, que está desarrollando herramientas de IA para optimizar la identificación de pacientes y mejorar la eficacia de los ensayos clínicos. La empresa mantiene asociaciones estratégicas con Quantify Research y AstraZeneca Canadá para avanzar en los enfoques de medicina de precisión en el desarrollo terapéutico del cáncer.
Onco-Innovations (OTCQB:ONNVF) CEO 토마스 오쇼너시는 Conversations That Matter에서 독점 인터뷰에 출연하여 암 치료 및 인공지능 통합에 대한 회사의 발전을 논의했습니다. 인터뷰에서는 다음과 같은 내용이 강조되었습니다:
회사가 전통적인 치료법을 개선하기 위해 정밀 의학을 활용하여 대장암 및 고형 종양에 대한 새로운 치료법 개발에 집중하고 있다는 점입니다. 알버타 대학교 암 연구소의 과학자들이 개발한 그들의 독점 기술은 표적 억제제와 나노기술을 사용하여 암세포 복제를 방해하면서 건강한 조직을 보존합니다.
인터뷰에서는 또한 Inka Health AI의 최근 인수에 대해 다루었으며, 이는 환자 식별 최적화 및 임상 시험의 효율성을 향상시키기 위한 AI 도구를 개발하고 있습니다. 이 회사는 정밀 의학 접근 방식을 암 치료 개발에 진전시키기 위해 Quantify Research 및 AstraZeneca Canada와 전략적 파트너십을 유지하고 있습니다.
Onco-Innovations (OTCQB:ONNVF) Le PDG Thomas O'Shaughnessy a été présenté dans une interview exclusive sur Conversations That Matter, où il a discuté des développements de l'entreprise dans le traitement du cancer et l'intégration de l'IA. L'interview a mis en lumière :
Le focus de l'entreprise sur le développement de traitements novateurs pour le cancer colorectal et les tumeurs solides, en utilisant la médecine de précision pour améliorer les thérapies traditionnelles. Leur technologie propriétaire, développée par des scientifiques de l'Institut du cancer de l'Université de l'Alberta, utilise des inhibiteurs ciblés et la nanotechnologie pour perturber la réplication des cellules cancéreuses tout en préservant les tissus sains.
L'interview a également abordé leur récente acquisition de Inka Health AI, qui développe des outils d'IA pour optimiser l'identification des patients et améliorer l'efficacité des essais cliniques. L'entreprise entretient des partenariats stratégiques avec Quantify Research et AstraZeneca Canada pour faire avancer les approches de médecine de précision dans le développement thérapeutique du cancer.
Onco-Innovations (OTCQB:ONNVF) CEO Thomas O'Shaughnessy wurde in einem exklusiven Interview bei Conversations That Matter vorgestellt, in dem er über die Entwicklungen des Unternehmens in der Krebsbehandlung und die Integration von KI sprach. Das Interview hob hervor:
Den Fokus des Unternehmens auf die Entwicklung neuartiger Behandlungen für kolorektalen Krebs und solide Tumoren, wobei Präzisionsmedizin eingesetzt wird, um traditionelle Therapien zu verbessern. Ihre proprietäre Technologie, entwickelt von Wissenschaftlern des Alberta Cancer Institute, verwendet gezielte Inhibitoren und Nanotechnologie, um die Replikation von Krebszellen zu stören und gleichzeitig gesundes Gewebe zu erhalten.
Das Interview behandelte auch ihre kürzliche Übernahme von Inka Health AI, das KI-Tools entwickelt, um die Patientenidentifikation zu optimieren und die Effizienz klinischer Studien zu verbessern. Das Unternehmen pflegt strategische Partnerschaften mit Quantify Research und AstraZeneca Kanada, um Fortschritte bei der Präzisionsmedizin in der Krebsbehandlung zu erzielen.
- Strategic acquisition of Inka Health AI to enhance clinical trials
- Partnerships with major players: AstraZeneca Canada and Quantify Research
- Proprietary cancer treatment technology from University of Alberta Cancer Institute
- None.
VANCOUVER, BC / ACCESS Newswire / March 2, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt: W1H)(WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that its CEO, Thomas O'Shaughnessy, was recently featured in an exclusive interview on Conversations That Matter, a widely distributed long-form program showcasing thought leaders shaping the world. The program is featured in the Vancouver Sun and is broadcast across multiple television networks in British Columbia, Canada, including CHEK-TV, as well as on digital platforms. In this exclusive interview, O'Shaughnessy shared Onco-Innovations' efforts towards developing a novel treatment candidate for colorectal cancer and other solid tumours, as well as the Company's distinguished scientific team, its recent strategic acquisition of Inka Health AI, and the Company's progress toward advancing clinical trials.
The interview delved into Onco-Innovations' pioneering approach to research and development regarding cancer treatment, which focuses on precision medicine to enhance the effectiveness of traditional therapies such as chemotherapy and radiation. O'Shaughnessy highlighted the Company's proprietary technology, developed by leading scientists from the University of Alberta Cancer Institute, including the use of targeted inhibitors and nanotechnology to disrupt cancer cell replication while preserving healthy tissue. He also discussed how the recently-acquired Inka Health AI is developing tools to leverage artificial intelligence to optimize patient identification and enhance clinical trial efficacy. Through this acquisition, he added, Onco-Innovations will continue to focus on building partnerships with research organizations such as Quantify Research, and big-pharma, such as AstraZeneca Canada, collaborations that the Company believes will play a crucial role in advancing a precision medicine approach to cancer therapeutic development.
"Being featured on Conversations That Matter gives us an incredible opportunity to share Onco-Innovations' story and reach a broader audience. It's vital for us to communicate the novel work we're doing in precision cancer therapeutic development and how we're striving to develop innovative therapies," said Thomas O'Shaughnessy, CEO of Onco-Innovations. "We are committed to advancing our research, accelerating clinical trials, and ultimately making a global impact in the fight against cancer."
You can watch the interview online at the Conversations That Matter website, their YouTube channel, their Vimeo channel, and the Vancouver Sun website. It will also be broadcast on British Columbia based stations, CHEK-TV, CFTK-TV, CJDC-TV, and CKFR-AM. Please check the individual station websites for specific air dates and times.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com
The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.
Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Company's research initiatives, and the prospects of the Company, including its ability to safeguard its technologies, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize any of the Company's technologies, the failure to receive a patent or to otherwise safeguard the Company's intellectual property rights, the failure to successfully complete further trials and studies, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
FAQ
What is Onco-Innovations' (ONNVF) approach to cancer treatment development?
How will the Inka Health AI acquisition benefit ONNVF's clinical trials?
Who are Onco-Innovations' (ONNVF) key strategic partners in cancer research?
What types of cancer is ONNVF targeting with their treatment candidate?
